BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 23280418)

  • 1. Tumor necrosis factor-inhibiting therapy preferentially targets bone destruction but not synovial inflammation in a tumor necrosis factor-driven model of rheumatoid arthritis.
    Binder NB; Puchner A; Niederreiter B; Hayer S; Leiss H; Blüml S; Kreindl R; Smolen JS; Redlich K
    Arthritis Rheum; 2013 Mar; 65(3):608-17. PubMed ID: 23280418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis.
    Polzer K; Neubert K; Meister S; Frey B; Baum W; Distler JH; Gückel E; Schett G; Voll RE; Zwerina J
    Arthritis Rheum; 2011 Mar; 63(3):670-80. PubMed ID: 21360496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction.
    Zwerina J; Hayer S; Redlich K; Bobacz K; Kollias G; Smolen JS; Schett G
    Arthritis Rheum; 2006 Feb; 54(2):463-72. PubMed ID: 16447221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha.
    Dai SM; Nishioka K; Yudoh K
    Ann Rheum Dis; 2004 Nov; 63(11):1379-86. PubMed ID: 15479886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiinflammatory effects of tumor necrosis factor on hematopoietic cells in a murine model of erosive arthritis.
    Blüml S; Binder NB; Niederreiter B; Polzer K; Hayer S; Tauber S; Schett G; Scheinecker C; Kollias G; Selzer E; Bilban M; Smolen JS; Superti-Furga G; Redlich K
    Arthritis Rheum; 2010 Jun; 62(6):1608-19. PubMed ID: 20155834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice.
    Li P; Schwarz EM; O'Keefe RJ; Ma L; Looney RJ; Ritchlin CT; Boyce BF; Xing L
    Arthritis Rheum; 2004 Jan; 50(1):265-76. PubMed ID: 14730625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
    Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
    Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis.
    Korb-Pap A; Stratis A; Mühlenberg K; Niederreiter B; Hayer S; Echtermeyer F; Stange R; Zwerina J; Pap T; Pavenstädt H; Schett G; Smolen JS; Redlich K
    Ann Rheum Dis; 2012 Jun; 71(6):1004-11. PubMed ID: 22258493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis.
    Redlich K; Görtz B; Hayer S; Zwerina J; Doerr N; Kostenuik P; Bergmeister H; Kollias G; Steiner G; Smolen JS; Schett G
    Am J Pathol; 2004 Feb; 164(2):543-55. PubMed ID: 14742260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation.
    Vandooren B; Cantaert T; Noordenbos T; Tak PP; Baeten D
    Arthritis Rheum; 2008 Mar; 58(3):718-29. PubMed ID: 18311801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis.
    Cejka D; Hayer S; Niederreiter B; Sieghart W; Fuereder T; Zwerina J; Schett G
    Arthritis Rheum; 2010 Aug; 62(8):2294-302. PubMed ID: 20506288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
    Axmann R; Böhm C; Krönke G; Zwerina J; Smolen J; Schett G
    Arthritis Rheum; 2009 Sep; 60(9):2747-56. PubMed ID: 19714627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
    Zhang Q; Badell IR; Schwarz EM; Boulukos KE; Yao Z; Boyce BF; Xing L
    Arthritis Rheum; 2005 Sep; 52(9):2708-18. PubMed ID: 16142752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Requirement of methotrexate in combination with anti-tumor necrosis factor-alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis.
    Matsuno H; Yoshida K; Ochiai A; Okamoto M
    J Rheumatol; 2007 Dec; 34(12):2326-33. PubMed ID: 18050387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
    Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
    Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoimmunity and bone.
    Schwarz EM; Looney RJ; Drissi MH; O'Keefe RJ; Boyce BF; Xing L; Ritchlin CT
    Ann N Y Acad Sci; 2006 Apr; 1068():275-83. PubMed ID: 16831928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoclasts are essential for TNF-alpha-mediated joint destruction.
    Redlich K; Hayer S; Ricci R; David JP; Tohidast-Akrad M; Kollias G; Steiner G; Smolen JS; Wagner EF; Schett G
    J Clin Invest; 2002 Nov; 110(10):1419-27. PubMed ID: 12438440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis.
    Li P; Schwarz EM; O'Keefe RJ; Ma L; Boyce BF; Xing L
    J Bone Miner Res; 2004 Feb; 19(2):207-13. PubMed ID: 14969390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nurse-like cells from patients with rheumatoid arthritis support the survival of osteoclast precursors via macrophage colony-stimulating factor production.
    Tsuboi H; Udagawa N; Hashimoto J; Yoshikawa H; Takahashi N; Ochi T
    Arthritis Rheum; 2005 Dec; 52(12):3819-28. PubMed ID: 16320327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.